Skip to main content

The CAR-T cell therapy market is estimated to be worth USD 14 billion in 2030, predicts Roots Analysis

  

Given their ability to selectively direct a cell mediated immune response against cancer cells and, thereby, offer prolonged periods of disease remission, several CAR-T cell therapies are expected to achieve blockbuster status

 

Roots Analysis is pleased to announce the publication of its recent study, titled, “CAR-T Cell Therapies Market (3rd Edition) by Target Indications (NHL, Multiple Myeloma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Hepatocellular Carcinoma and Others), Target Antigens (CD19, BCMA, CD19 / CD22, GPC3 and EGFR), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) – Industry Trends and Global Forecasts, 2021-2030”

 

The features an extensive study of the current market landscape and the future potential of CAR-T cell therapies. The report highlights the efforts of both industry players and academic organizations in this rapidly evolving segment of the biopharmaceutical industry. Amongst other elements, the report features the following:

§  A detailed assessment of the current market landscape of drug developers engaged in the development of CAR-T cell therapies.

§  Detailed profiles of marketed and mid-to late stage clinical products (shortlisted on the basis of the stage of development).

§  An analysis of the CAR constructs of clinical-stage CAR-T therapies based on the generation of CAR-T therapy.

§  An analysis highlighting the key opinion leaders (KOLs) in this domain. It features a 2×2 matrix assessing the relative experience of KOLs shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field.

§  An analysis of the various CAR-T cell therapy focused clinical trials registered across the world, between 2009 and 2019.

§  An overview of the various focus therapeutic areas of therapy developers, including an assessment of the opportunity (in terms of revenue generation potential from therapy sales) across oncological and non-oncological disease indications.

§  A detailed discussion on innovative technology platforms that are being used for the development of CAR-T cell therapies.

§  An analysis of the partnerships that have been established in the recent past.

§  An analysis of the investments that have been made into companies that have proprietary CAR-T cell based products / technologies.

§  A case study on other T-cell based therapies, apart from CAR-Ts, including a detailed analysis of approved / pipeline products.

§  A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.

§  An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies.

§  An analysis of the prevalent and emerging trends in this domain, as represented on the social media platform, Twitter.

§  A review of the key promotional strategies that have been adopted by the developers of the marketed CAR-Tcell therapies.

§  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

 

§  To order this 795+ page report, which features 165+ figures and 270+ tables, please visit https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html

 

  • Type of target disease Indication
    • Non-Hodgkin’s lymphoma
    • Multiple myeloma
    • Melanoma
    • Chronic lymphocytic leukemia

§  Acute lymphoblastic leukemia

§  Follicular lymphoma

§  Mantle cell lymphoma

    • Hepatocellular carcinoma

§  Colorectal cancer

 

§  Type of Target Antigens

    • CD19
    • BCMA
    • CD19, CD22
    • GPC3
    • EGFR

 

§  Key Geographical Regions 

    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East and North Africa
    • Rest of the World 

 

§  Transcripts of interviews held with the following senior level representatives of stakeholder companies

  • Tim Oldham (Chief Executive Officer, cell therapies)
  • Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)
  • Wei (William) Cao (Co-Founder, Chairman and Chief Executive Officer, Gracell Biotechnologies)
  • Miguel Forte (Chief Operating Officer, TxCell)
  • Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
  • Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
  • Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
  • Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys)
  • Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)
  • Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)

 

§  To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/269/request-sample.html

Key companies covered in the report

  • Autolus
  • bluebird bio
  • CARsgen Therapeutics

§  Celgene (A Bristol Myers Squibb Company)

  • Cellectis
  • Cellular Biomedicine Group
  • Innovative Cellular Therapeutics
  • Iovance Biotherapeutics
  • Kite Pharma (A Gilead Sciences Company)
  • Kuur Therapeutics
  • Lion TCR
  • Noile-Immune Biotech
  • Novartis
  • Shanghai GeneChem
  • Sinobioway Cell Therapy
  • Takara Bio
  • Ziopharm Oncology

 

For more information please click on the following link:

https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html

 

Other Recent Offerings

1.  Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (5th Edition), 2021 – 2030

 

2. mRNA Therapeutics and Vaccines Market, 2020-2030

3. Gene Therapy Market (4th Edition): Industry Trends and Global Forecasts, 2020-2030

4. Oncolytic Virus Therapy Market: Pipeline Review, Developer Landscape and Competitive Insights, 2020-2030

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

Facebook - https://www.facebook.com/RootsAnalysis

LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/

Twitter - https://twitter.com/RootsAnalysis
Labels:

Comments

Post a Comment

Popular posts from this blog

The gene therapy market is projected to be worth USD 14.6 billion in 2030, growing at a CAGR of 30%, over the next decade, claims Roots Analysis

  Roots Analysis has announced the addition of “ Gene Therapy Market (4th Edition), 2020-2030” report to its list of offerings.   Success of approved gene therapies has resulted in a surge in interest of biopharmaceutical developers in this rapidly evolving domain. Presently, the ability of gene therapies to treat diverse disease indications is considered among the most prominent drivers of this market. In addition, promising clinical results of pipeline candidates are anticipated to draw in more investments to support product development initiatives.   To order this 720+ page report, which features 220+ figures and 375+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html   Key Market Insights   Around 800 gene therapies are currently being developed across different stages Apart from 10 approved products, most of the aforementioned therapies (65%) are in the early stages of developmen...
Post a Comment
Read more

The synthetic lethality-based drugs and targets market is estimated to be worth USD 8 billion in 2030, predicts Roots Analysis

  Advances in molecular screening technology have enabled the identification of novel synthetic lethal gene combinations, enabling the development of lead candidates that leverage the aforementioned phenomenon to offer therapeutic benefit.   Roots Analysis is pleased to announce the publication of its recent study, titled, “ Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways ”.   The   report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of such compact diagnostic devices, over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes: §   A detailed assessment of the current market landscape, providing information on drug developer(s) phase of development, type of ...
Post a Comment
Read more

The “China Pharmaceutical Contract Manufacturing Services Market, 2020-2030” report features an extensive study of the current market landscape and future opportunities associated with the pharmaceutical contract manufacturing market in China.

  Key Inclusions §   A review of the current market landscape of companies offering pharmaceutical contract manufacturing services in China, along with information on year of establishment, company size, location of headquarters, type of product (active pharmaceutical ingredients (APIs), intermediates and finished dosage formulations (FDFs)), type of FDFs, type of packaging and number of manufacturing facilities. §   A detailed landscape of the pharmaceutical manufacturing facilities in China, including an analysis based on location of these facilities, highlighting key manufacturing hubs. §   A brief discussion of various guidelines laid down by regulatory authorities in China for the manufacturing of pharmaceuticals. It also provides information on various challenges, related to regulatory scrutiny, faced by pharmaceutical manufacturers in China. §   Elaborate profiles of key players that offer a diverse range of capabilities for the manufacturing of p...
Post a Comment
Read more